Zenocutuzumab granted US Fast Track designation for the treatment of Neuregulin 1 fusion cancers

The Phase 1/2 energy trial, which is currently recruiting, will evaluate zenocutuzumab monotherapy in patients with NRG1 gene fusion positive cancers, including non-small cell lung cancer, pancreatic cancer and other solid tumours.

Source:

Biospace Inc.